Literature DB >> 12220741

Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP.

M Laburthe1, A Couvineau.   

Abstract

VIP and PACAP are two prominent neuropeptides which share two common G protein-coupled receptors VPAC1 and VPAC2 while PACAP has an additional specific receptor PAC1. This paper reviews the present knowledge regarding three aspects of VPAC receptors including: (i). receptor specificity towards natural VIP-related peptides and pharmacology of synthetic agonists or antagonists; (ii). receptor signaling; (iii). molecular basis of ligand-receptor interaction as determined by site-directed mutagenesis, construction of receptor chimeras and structural modeling.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12220741     DOI： 10.1016/s0167-0115(02)00099-x

Source DB:  PubMed          Journal:  Regul Pept        ISSN： 0167-0115


  44 in total

1.  Mechanisms of VIP-induced inhibition of the lymphatic vessel pump.

Authors:  Pierre-Yves von der Weid; Sonia Rehal; Peter Dyrda; Stewart Lee; Ryan Mathias; Mozibur Rahman; Simon Roizes; Mohammad S Imtiaz
Journal:  J Physiol       Date:  2012-03-25       Impact factor: 5.182

Review 2.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Anatomical and functional characterization of clock gene expression in neuroendocrine dopaminergic neurons.

Authors:  Michael T Sellix; Marcel Egli; Maristela O Poletini; De'Nise T McKee; Matthew D Bosworth; Cheryl A Fitch; Marc E Freeman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-12-22       Impact factor: 3.619

4.  Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells.

Authors:  Wanhong Ding; Michela Manni; Lori L Stohl; Xi K Zhou; John A Wagner; Richard D Granstein
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

5.  Gastric motility in soluble guanylate cyclase alpha 1 knock-out mice.

Authors:  Gwen Vanneste; Ingeborg Dhaese; Patrick Sips; Emmanuel Buys; Peter Brouckaert; Romain A Lefebvre
Journal:  J Physiol       Date:  2007-08-23       Impact factor: 5.182

Review 6.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

7.  Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS.

Authors:  Chaohong Sun; Danying Song; Rachel A Davis-Taber; Leo W Barrett; Victoria E Scott; Paul L Richardson; Ana Pereda-Lopez; Marie E Uchic; Larry R Solomon; Marc R Lake; Karl A Walter; Philip J Hajduk; Edward T Olejniczak
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

8.  Caveolae-dependent internalization and homologous desensitization of VIP/PACAP receptor, VPAC₂, in gastrointestinal smooth muscle.

Authors:  Sunila Mahavadi; Sayak Bhattacharya; Jennnifer Kim; Sally Fayed; Othman Al-Shboul; John R Grider; Karnam S Murthy
Journal:  Peptides       Date:  2013-03-15       Impact factor: 3.750

9.  Differential activation of guinea pig intrinsic cardiac neurons by the PAC1 agonists maxadilan and pituitary adenylate cyclase-activating polypeptide 27 (PACAP27).

Authors:  Donald B Hoover; John D Tompkins; Rodney L Parsons
Journal:  J Pharmacol Exp Ther       Date:  2009-07-14       Impact factor: 4.030

Review 10.  Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

Authors:  S G R Smalley; P A Barrow; N Foster
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.